Valid Ghana · FDA Ghana

CLINDAMED 300

CLINDAMED

FDA/SD.265-030326 CLINDAMED 300MG

What it does

Clindamed is an antibiotic used to treat various bacterial infections.

Commonly used for: skin infections, respiratory tract infections, bone infections, pelvic infections

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.

Sourcing - Kenya only

Registration & product details

Registration no.
FDA/SD.265-030326
Registration date
2026-03-19
Expiry date
2031-06-01
Status
Valid
Active ingredient
CLINDAMED
Dosage form
CLINDAMED
Strength
300MG
Pack size
-
Therapeutic class
-
Manufacturer / MAH
Centurion Laboratories
Country of origin
INDIA
Manufacturer location
Biotech Park, P-2, GIDC Savli, Manjusar, Gujarat 391776, India

Source: Food and Drugs Authority · fetched 2026-05-22 02:34:38 · updated 2026-09-18 04:00:06

Disclaimer: This information is sourced from Food and Drugs Authority (Ghana). Always consult a qualified healthcare professional before using any medication.

About this medicine

Clindamed is an antibiotic used to treat various bacterial infections.

What it treats

  • skin infections
  • respiratory tract infections
  • bone infections
  • pelvic infections

How it works

Clindamed works by stopping the growth of bacteria, helping to clear the infection from the body.

Who it's for

It is prescribed for people with bacterial infections who need antibiotic treatment.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: clindamed

BNF-referenced

Clindamed, also known as clindamycin, is an antibiotic that belongs to the lincosamide class. It is effective against a variety of gram-positive bacteria and anaerobic organisms. Clindamed is used to treat various infections, including skin and soft tissue infections, respiratory tract infections, and certain types of bone infections. Its mechanism of action involves inhibiting bacterial protein synthesis, making it a valuable option for treating infections caused by susceptible strains.

Indications

  • Skin and soft tissue infections
  • Respiratory tract infections
  • Bone and joint infections
  • Intra-abdominal infections
  • Pelvic inflammatory disease

Dosage

Children: Refer to BNF for Children for appropriate dosing based on weight and age, typically 8 to 25 mg/kg/day divided into doses every 6 to 8 hours.

Adults: Refer to BNF for specific dosing, typically 150 mg to 450 mg every 6 to 8 hours depending on the severity and site of infection.

Mechanism of action

Clindamycin exerts its antibacterial effects by binding to the 50S ribosomal subunit of bacteria, inhibiting peptide bond formation and protein synthesis. This action affects the growth and replication of bacteria, leading to their eventual death. Clindamycin is particularly effective against anaerobic bacteria and some protozoa.

Pharmacodynamics

Clindamycin demonstrates bacteriostatic activity against a wide range of gram-positive bacteria and anaerobic organisms. Its effectiveness is influenced by the susceptibility of the target organisms and the concentration of the drug at the site of infection. Resistance may develop through modification of the ribosomal target or enzymatic inactivation.

Pharmacokinetics

Clindamycin is well-absorbed after oral administration, with bioavailability typically around 90%. It is widely distributed in body tissues and fluids, including bone, and can penetrate well into abscesses. Clindamycin is metabolized in the liver and has a half-life of approximately 2.5 to 3 hours. The drug is primarily excreted in urine as metabolites, with less than 10% excreted unchanged.

Contra-indications

  • Hypersensitivity to clindamycin or any component of the formulation
  • Previous history of severe adverse reactions to lincomycin
  • Caution in patients with a history of gastrointestinal disease, particularly colitis

Adverse effects

  • Nausea
  • Diarrhea
  • Abdominal pain
  • Rash
  • Increased liver enzymes
  • Pseudomembranous colitis

Interactions

  • May enhance the effects of neuromuscular blocking agents
  • Antidiarrheal agents may prolong or worsen colitis
  • Use caution when combined with other drugs that affect liver enzymes

Precautions

  • Monitor for signs of gastrointestinal disturbances
  • Discontinue therapy if severe diarrhea occurs
  • Use caution in patients with renal impairment

Pregnancy

Clindamycin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Clindamycin is excreted in breast milk, caution is advised when administering to nursing mothers.

Storage

Store at room temperature, away from moisture and heat.

Formulations

  • Clindamycin oral capsules
  • Clindamycin topical gel
  • Clindamycin injectable solution

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Molecular reference: clindamed

PubChem CID 16051951

Molecular formula: C18H34Cl2N2O5S

Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.